These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30711978)

  • 1. Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
    Matsuoka H; Nakamura K; Matsubara Y; Ida N; Nishida T; Ogawa C; Katsi K; Kanazawa S; Masuyama H
    Anticancer Res; 2019 Feb; 39(2):933-939. PubMed ID: 30711978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy.
    Kiyotoki T; Nakamura K; Haraga J; Omichi C; Ida N; Saijo M; Nishida T; Kusumoto T; Masuyama H
    Int J Gynecol Cancer; 2018 Jan; 28(1):168-175. PubMed ID: 29040185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
    Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy.
    Kise S; Arakaki Y; Kudaka W; Ariga T; Kinjo N; Kohatu H; Aoki Y
    Anticancer Res; 2022 Oct; 42(10):4887-4893. PubMed ID: 36191992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia as a Predictor of Survival Among Patients With Organ Metastatic Cervical Cancer.
    Yoshikawa N; Shirakawa A; Yoshida K; Tamauchi S; Suzuki S; Kikkawa F; Kajiyama H
    Nutr Clin Pract; 2020 Dec; 35(6):1041-1046. PubMed ID: 32253779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy.
    Cho WK; Yu JI; Park HC; Lim DH; Kim TH; Chie EK
    Tumori; 2021 Jun; 107(3):247-253. PubMed ID: 32646298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 9. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
    Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
    Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
    Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
    Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy.
    Haraga J; Nakamura K; Omichi C; Nishida T; Haruma T; Kusumoto T; Seki N; Masuyama H; Katayama N; Kanazawa S; Hiramatsu Y
    Mol Clin Oncol; 2016 Nov; 5(5):567-574. PubMed ID: 27900086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis.
    Katsui K; Ogata T; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Sci Rep; 2021 Jun; 11(1):11882. PubMed ID: 34088965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer.
    Mizunuma M; Yokoyama Y; Futagami M; Aoki M; Takai Y; Mizunuma H
    Int J Clin Oncol; 2015 Oct; 20(5):989-96. PubMed ID: 25736530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy.
    Abe A; Yuasa M; Imai Y; Kagawa T; Mineda A; Nishimura M; Tonoiso C; Kubo A; Kawanaka T; Ikushima H; Iwasa T
    Int J Clin Oncol; 2022 May; 27(5):983-991. PubMed ID: 35212828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of outcomes for patients with cervical cancer who developed bone metastasis after the primary treatment with concurrent chemoradiation versus radiation therapy alone.
    Nartthanarung A; Thanapprapasr D
    Int J Gynecol Cancer; 2010 Nov; 20(8):1386-90. PubMed ID: 21051982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer.
    Ma DW; Cho Y; Jeon MJ; Kim JH; Lee IJ; Youn YH; Park JJ; Jung DH; Park H; Lee CG; Kim JW; Jeung HC
    Front Oncol; 2019; 9():366. PubMed ID: 31139564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.